Cancer Medicine
Open Access
ORIGINAL RESEARCH
Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer Yizhuo Wang1, Chang Wang1, Huijie Xiao2, Chao Niu1, Haitao Wu1, Haofan Jin1, Cheng Yao1, Hua He1, Huimin Tian1, Fujun Han1, Dan Li1, Wei Han1, Jianting Xu1, Jingtao Chen1,3, Jiuwei Cui1 & Wei Li1 1Cancer
Center, the First Hospital of Jilin University, Changchun, China of Gastrointestinal Colorectal and Anal Surgery, China–Japan Union Hospital of Jilin University, Changchun, China 3Institute of Translational Medicine, the First Hospital of Jilin University, Changchun 130031, China 2Department
Keywords Cellular immunotherapy, chemotherapy, disease-free survival, gastric cancer, overall survival Correspondence: Wei Li or Jiuwei Cui, Cancer Center, the First Hospital of Jilin University, Xinmin Street, Changchun 130021, Jilin, China. Tel: +86043188782178; Fax: +86043188786134; E-mails: [email protected]; cuijw@jlu. edu.cn Funding Information This work was supported by the Jilin Provincial Science and Technology Department (Grants 20111807 and 20140414014GH, and 20150101176 to J. C.), the Key Project of Science and Technology Research of the Ministry of Education (Grant 311015 to J. C.), the Platform Construction Project of Development and Reform Commission of Jilin Province (Grant 2014N147 to J. C.), the Bethune Program B of Jilin University (Grant 2012202 to J. C.), the Key Clinical Project of the Ministry of Health of the People’s Republic of China (Grant 2001133 to W. L.), and the National Major Scientific and Technological Special Project (Grant 2013ZX09102032 to J. C.). Received: 3 August 2016; Revised: 16 September 2016; Accepted: 26 September 2016
Abstract Postsurgical relapse remains a common issue for resectable gastric cancer (GC). Here, we investigated the efficacy and safety of an adjuvant treatment combining chemotherapy with cellular immunotherapy (CIT) using autologous natural killer cells, γδT cells, and cytokine-induced killer cells in the treatment of stage II/III GC. A pilot prospective cohort study was conducted in 169 patients with stage II/III GC who had undergone gastrectomy with D2 lymph node dissection. Patients were assigned into two groups according to the patient choice of treatment, including chemotherapy alone (chemo) or chemotherapy combined with CIT (chemo/CIT). Disease-free survival (DFS), overall survival (OS), and adverse events were evaluated. Univariate and multivariate Cox models were used to analyze the impact of chemo/CIT on DFS and OS. Kaplan–Meier analysis with the log-rank test was used to compare the clinical outcome between two groups. Three-year DFS rate was 60.6% and 74.7% (P = 0.036) and 3-year OS rate was 64.9% and 83% (P = 0.051) for the chemo and chemo/ CIT group, respectively. TNM stage and chemo/CIT were independent prognostic factors for both DFS (for TNM stage, P
Open Access
ORIGINAL RESEARCH
Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer Yizhuo Wang1, Chang Wang1, Huijie Xiao2, Chao Niu1, Haitao Wu1, Haofan Jin1, Cheng Yao1, Hua He1, Huimin Tian1, Fujun Han1, Dan Li1, Wei Han1, Jianting Xu1, Jingtao Chen1,3, Jiuwei Cui1 & Wei Li1 1Cancer
Center, the First Hospital of Jilin University, Changchun, China of Gastrointestinal Colorectal and Anal Surgery, China–Japan Union Hospital of Jilin University, Changchun, China 3Institute of Translational Medicine, the First Hospital of Jilin University, Changchun 130031, China 2Department
Keywords Cellular immunotherapy, chemotherapy, disease-free survival, gastric cancer, overall survival Correspondence: Wei Li or Jiuwei Cui, Cancer Center, the First Hospital of Jilin University, Xinmin Street, Changchun 130021, Jilin, China. Tel: +86043188782178; Fax: +86043188786134; E-mails: [email protected]; cuijw@jlu. edu.cn Funding Information This work was supported by the Jilin Provincial Science and Technology Department (Grants 20111807 and 20140414014GH, and 20150101176 to J. C.), the Key Project of Science and Technology Research of the Ministry of Education (Grant 311015 to J. C.), the Platform Construction Project of Development and Reform Commission of Jilin Province (Grant 2014N147 to J. C.), the Bethune Program B of Jilin University (Grant 2012202 to J. C.), the Key Clinical Project of the Ministry of Health of the People’s Republic of China (Grant 2001133 to W. L.), and the National Major Scientific and Technological Special Project (Grant 2013ZX09102032 to J. C.). Received: 3 August 2016; Revised: 16 September 2016; Accepted: 26 September 2016
Abstract Postsurgical relapse remains a common issue for resectable gastric cancer (GC). Here, we investigated the efficacy and safety of an adjuvant treatment combining chemotherapy with cellular immunotherapy (CIT) using autologous natural killer cells, γδT cells, and cytokine-induced killer cells in the treatment of stage II/III GC. A pilot prospective cohort study was conducted in 169 patients with stage II/III GC who had undergone gastrectomy with D2 lymph node dissection. Patients were assigned into two groups according to the patient choice of treatment, including chemotherapy alone (chemo) or chemotherapy combined with CIT (chemo/CIT). Disease-free survival (DFS), overall survival (OS), and adverse events were evaluated. Univariate and multivariate Cox models were used to analyze the impact of chemo/CIT on DFS and OS. Kaplan–Meier analysis with the log-rank test was used to compare the clinical outcome between two groups. Three-year DFS rate was 60.6% and 74.7% (P = 0.036) and 3-year OS rate was 64.9% and 83% (P = 0.051) for the chemo and chemo/ CIT group, respectively. TNM stage and chemo/CIT were independent prognostic factors for both DFS (for TNM stage, P
